The Goldman Sachs Group Trims Natera (NASDAQ:NTRA) Target Price to $80.00

Natera (NASDAQ:NTRAGet Rating) had its target price reduced by investment analysts at The Goldman Sachs Group from $90.00 to $80.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. The Goldman Sachs Group’s price target indicates a potential upside of 103.15% from the company’s current price.

NTRA has been the topic of a number of other reports. Robert W. Baird cut their price objective on Natera from $152.00 to $100.00 and set an “outperform” rating on the stock in a report on Friday, February 25th. Piper Sandler lifted their target price on Natera from $70.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, April 13th. BTIG Research reduced their price objective on Natera from $125.00 to $100.00 in a research report on Thursday, March 10th. Zacks Investment Research lowered Natera from a “hold” rating to a “sell” rating in a report on Wednesday, January 12th. Finally, Wells Fargo & Company lowered their target price on Natera from $135.00 to $100.00 in a research note on Monday, January 24th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $115.25.

Shares of Natera stock traded up $1.44 on Tuesday, reaching $39.38. The company’s stock had a trading volume of 16,527 shares, compared to its average volume of 2,396,452. The stock has a 50-day moving average price of $49.75 and a 200-day moving average price of $78.26. Natera has a 52-week low of $26.10 and a 52-week high of $129.09. The company has a market capitalization of $3.76 billion, a P/E ratio of -7.47 and a beta of 1.20. The company has a quick ratio of 4.87, a current ratio of 4.99 and a debt-to-equity ratio of 0.43.

Natera (NASDAQ:NTRAGet Rating) last issued its quarterly earnings data on Thursday, February 24th. The medical research company reported ($1.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.24) by ($0.24). The business had revenue of $173.00 million for the quarter, compared to analyst estimates of $168.59 million. Natera had a negative return on equity of 90.55% and a negative net margin of 75.43%. The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.89) earnings per share. Sell-side analysts forecast that Natera will post -6.05 earnings per share for the current fiscal year.

In other Natera news, CEO Steven Leonard Chapman sold 3,686 shares of the business’s stock in a transaction that occurred on Monday, January 24th. The stock was sold at an average price of $59.95, for a total value of $220,975.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Robert Alan Schueren sold 2,378 shares of the company’s stock in a transaction on Monday, January 24th. The stock was sold at an average price of $59.95, for a total value of $142,561.10. The disclosure for this sale can be found here. Insiders sold a total of 21,625 shares of company stock worth $1,030,661 over the last quarter. Company insiders own 10.86% of the company’s stock.

Large investors have recently made changes to their positions in the stock. ProShare Advisors LLC grew its position in shares of Natera by 7.0% in the 4th quarter. ProShare Advisors LLC now owns 2,209 shares of the medical research company’s stock worth $206,000 after acquiring an additional 145 shares in the last quarter. Evolution Wealth Advisors LLC grew its stake in Natera by 148.6% in the third quarter. Evolution Wealth Advisors LLC now owns 261 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 156 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in shares of Natera by 6.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 2,904 shares of the medical research company’s stock worth $271,000 after buying an additional 166 shares during the last quarter. Captrust Financial Advisors lifted its holdings in shares of Natera by 24.1% during the third quarter. Captrust Financial Advisors now owns 910 shares of the medical research company’s stock worth $101,000 after buying an additional 177 shares during the last quarter. Finally, Xponance Inc. lifted its holdings in shares of Natera by 2.1% during the 3rd quarter. Xponance Inc. now owns 8,660 shares of the medical research company’s stock worth $965,000 after acquiring an additional 182 shares during the period.

Natera Company Profile (Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Articles

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.